Biolipox Year-End Report 2006

* Revenues for the year amounted to SEK 40.5 million (147.0). For the fourth quarter revenues amounted to SEK 7.8 million (147.0).

* Earnings after tax for the year amounted to SEK -70.5 million (34.7). For the fourth quarter earnings after tax amounted to SEK -21.3 million (112.6).

* Earnings per share for the year was SEK -98.50 (7.80). For the fourth quarter earnings per share was SEK -28.37 (105.56).

* Cash flow for the year was negative and amounted to SEK -32.4 million (156.6). For the fourth quarter cash flow was negative and amounted to SEK -23.6 million (88.1).

* Biolipox selects a new class of drug candidate in asthma project.

* Biolipox determines formulation of new allergy drug.

* Biolipox strengthens the R&D organization.



Forthcoming financial information

* Interim report, January - March 2007 10 May 2007
* Interim report, January - June 2007 29 August 2007
* Interim report, January - September 2007 18 October 2007


Biolipox’s year-end report 2006 is presented on the following pages.



For further information, please contact:
Torbjörn Bjerke, President & CEO, Tel: +46-70-866 19 90,
e-mail: torbjorn.bjerke@biolipox.com
Peter Hein, VP & CFO, Tel: +46-8-524 831 10, or +46-73-370 73 43,
e-mail: peter.hein@biolipox.com